{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088342","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.672809+00:00","generated_at":"2026-06-12T03:55:02.557390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cara Therapeutics Q2 2023 net loss $31.5M; revenue $6.9M down from $23.0M","bullets":["Net loss of $31.5M ($0.58 per share) vs $4.2M ($0.08 per share) in Q2 2022.","Total revenue $6.9M, down 70% YoY; Q2 2022 included $15M milestone.","KORSUVA injection net sales $11.4M; collaborative revenue $5.4M; vial orders up 46% QoQ.","Cash and marketable securities $101.7M at June 30, 2023, down from $156.7M at Dec 31, 2022.","CMS proposed ESRD PPS rule includes additional funding for TDAPA products; final rule expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088342","json":"https://secwatch.observer/filing/0001104659-23-088342.json","markdown":"https://secwatch.observer/filing/0001104659-23-088342.md","text":"https://secwatch.observer/filing/0001104659-23-088342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923088342/0001104659-23-088342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923088342/tm2322717d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:55:02.557390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60aae597e8af35ad2b7018aa142c8e0bb8db8479","claim":"Tvardi Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $6.9 million (total revenue), net income ($31.5 million) net loss, EPS ($0.58) per basic and diluted share.","evidence_excerpt":"or $(0.58) per basic and diluted share, compared to net loss of $4.2 million, or $(0.08) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.9 million and $23.0 million for the three months ended June 30, 2023 and 2022, respectively. Revenue primarily consisted of: · $5.4 million and $8.0 million of collaborative revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923088342/0001104659-23-088342-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$6.9 million (total revenue)"},{"label":"Net income","value":"($31.5 million) net loss"},{"label":"EPS","value":"($0.58) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}